Supplemental Information

Figure S1. QQ plots of the GWASs. (a) QQ plot of GWAS in individuals of European ancestry. (b) QQ plot of combined GWAS meta-analysis of all individuals.




Table S1. Characteristics of active surveillance patients included in the discovery and replication genome-wide association study.

	Discovery European 5,222			Replication							
Ancestral population			A	African 396		Asian 237		Latin American		Europeana	
Sample size								81	425		
Mean age (± s.d.)	63.5	(±7.2)	62	(±8.2)	63.8	(±7.7)	63	(±7.2)	64.4	(±8.2)	
Median follow-up time (months, IQR)	80	(51,112)	68	(40,106)	86	(54,118)	59	(33,85)	80	(31,110)	
Gleason grade											
GG1	4,819	(92%)	359	(91%)	219	(92%)	77	(95%)	372	(87%)	
GG2	344	(7%)	32	(8%)	15	(6%)	4	(5%)	48	(11%)	
≥ GG3	55	(1%)	4	(1%)	3	(1%)	0	(0%)	5	(1%)	
PSA (MAD)	5.0	(±2.1)	5.3	(±2.0)	5.3	(±2.5)	4.7	(±2.4)	4.1	(±2.2)	
Clinical tumor stage											
cT1	4,138	79%	322	81%	161	68%	66	81%	372	88%	
cT2	641	12%	49	12%	39	16%	9	11%	53	12%	
cT3 or cT4	34	1%	5	1%	5	2%	1	1%	0	0%	
Number of cores											
1-2	4,113	(79%)	298	(75%)	177	(75%)	67	(83%)	386	(91%)	
3	451	(9%)	44	(11%)	20	(8%)	7	(9%)	27	(6%)	
≥ 4	522	(10%)	39	(10%)	37	(16%)	7	(9%)	12	(3%)	
PC risk category											
Low	3,639	(70%)	262	(66%)	141	(59%)	59	(73%)	314	(74%)	
Intermediate	983	(19%)	82	(21%)	53	(22%)	14	(17%)	91	(21%)	
High	599	(11%)	52	(13%)	43	(18%)	8	(10%)	20	(5%)	

a. MD Anderson samples of European Ancestry.

IQR, interquartile range; MAD, median absolute deviation; PSA, prostate-specific antigen; PC, prostate cancer. Men of genetically inferred European ancestry genotyped by CIDR are included in the discovery GWAS. The other participants genotyped by CIDR and men from MD Anderson are included in the replication.

Age and cancer clinical characteristics were measured at diagnosis.

PC risk categories:

Low-risk patients had all the following criteria: GG1 only (Gleason \leq 3+3), PSA <10 ng/mL, clinical stage T1, and \leq 3 positive biopsy cores.

Intermediate-risk patients had any of the following, with no high-risk criteria: GG2 (Gleason 3+4), PSA 10-20 ng/mL, or clinical stage T2.

High-risk patients had any of the following: \geq GG3 (\geq Gleason 4+3), PSA \geq 20 ng/mL, clinical stage \geq T3, or \geq 4 positive biopsy cores.

Percentages do not all sum to 100% due to missingness.

Table S2. Hazard ratios for the association between time to AS failure with prostate cancer GRS.

	Minimally Adjusted			Fully Adjusted				
	HRª	95% CI	Р	HR⁵	95% CI	Р		
Decile								
0-10	0.73	0.60, 0.89	0.0016	0.69	0.56, 0.86	0.0010		
10-20	0.81	0.68, 0.98	0.030	0.83	0.68, 1.01	0.067		
20-30	0.93	0.78, 1.11	0.44	0.99	0.82, 1.20	0.95		
30-40	0.83	0.69, 0.99	0.041	0.82	0.67, 0.99	0.043		
40-60	1.00	Reference		1.00	Reference			
60-70	1.06	0.89, 1.26	0.50	1.03	0.86, 1.24	0.72		
70-80	1.10	0.92, 1.30	0.30	1.02	0.85, 1.22	0.87		
80-90	1.23	1.04, 1.46	0.014	1.15	0.96, 1.37	0.13		
90-100	1.27	1.07, 1.51	0.0061	1.13	0.94, 1.36	0.18		

HR = Hazard Ratio; CI = Confidence Interval

^a Hazard ratios are adjusted for age and the first 10 genetic principal components

^b Hazard ratios are adjusted for age, the first 10 genetic principal components, Gleason grade group (GG1, GG2, or ≥ GG3); PSA concentration (ng/mL); clinical stage (cT1, cT2, or cT3/cT4); and number of positive biopsy cores (1-2, 3, or ≥ 4).

Table S3. Hazard ratios for the association between time to AS failure with prostate-specific antigen GRS.

	Minimally Adjusted			Fully Adjusted				
	HRª	95% CI	Р	HR⁵	95% CI	Р		
Decile								
0-10	1.28	1.08, 1.52	0.0044	1.25	1.04, 1.50	0.017		
10-20	1.08	0.90, 1.29	0.40	1.01	0.83, 1.22	0.96		
20-30	1.15	0.97, 1.37	0.11	1.18	0.98, 1.42	0.083		
30-40	1.16	0.98, 1.38	0.088	1.16	0.96, 1.39	0.12		
40-60	1.00	Refere	nce	1.00	Referen	ce		
60-70	1.08	0.90, 1.29	0.40	1.05	0.86, 1.27	0.65		
70-80	1.00	0.83, 1.19	0.96	0.96	0.79, 1.17	0.70		
80-90	0.98	0.82, 1.18	0.84	1.02	0.84, 1.24	0.87		
90-100	0.95	0.79, 1.15	0.60	0.97	0.79, 1.19	0.78		

HR = Hazard Ratio; CI = Confidence Interval

^a Hazard ratios are adjusted for age and the first 10 genetic principal components

^b Hazard ratios are adjusted for age, the first 10 genetic principal components, Gleason grade group (GG1, GG2, or ≥ GG3); PSA concentration (ng/mL); clinical stage (cT1, cT2, or cT3/cT4); and number of positive biopsy cores (1-2, 3, or ≥ 4).

Table S4. ROC analysis of PC and PSA GRS compared to clinical characteristics for conversion from AS to treatment.

Model	GRS _{PC} ^d			GRS _{PSA} ^d			ALIC
Model	HR	95% CI	P-value	HR	95% CI	P-value	AUC
Reference model ^a							0.550
PC clinical characteristics ^b							0.653
PC clinical characteristics + PC GRS ^c	1.13	1.07, 1.19	3.3×10^{-6}				0.659
PC clinical characteristics + PSA GRS ^c				0.94	0.89, 0.98	8.5×10^{-3}	0.655
PC clinical characteristics + PC GRS + PSA GRS	1.15	1.09, 1.22	1.5×10^{-7}	0.91	0.87, 0.96	3.0×10^{-4}	0.661

^a All models contain age and the first 10 principal components. ^b PC clinical characteristics were Gleason grade group (GG1, GG2, or ≥ GG3); PSA concentration (ng/mL); clinical stage (cT1, cT2, or cT3/cT4); and number of positive biopsy cores (1-2, 3, or ≥ 4).

° PC GRS is constructed from 269 prostate cancer associated variants, while PSA GRS is derived from 36 PSA risk variants.

^d The test statistics of GRS_{PC} and GRS_{PSA} are reported when the model contains them.